CARs are sharpening their weapons.
作者信息
Pievani Alice, Biondi Marta, Tettamanti Sarah, Biondi Andrea, Dotti Gianpietro, Serafini Marta
机构信息
Tettamanti Center and Pediatrics, Fondazione IRCCS San Gerardo dei Tintori, Monza, Italy.
School of Medicine and Surgery, University of Milan-Bicocca, Milano, Italy.
出版信息
J Immunother Cancer. 2024 Jan 31;12(1):e008275. doi: 10.1136/jitc-2023-008275.
Abstract
摘要
相似文献
1
CARs are sharpening their weapons.
J Immunother Cancer. 2024 Jan 31;12(1):e008275. doi: 10.1136/jitc-2023-008275.
2
The promise and potential pitfalls of chimeric antigen receptors.
Curr Opin Immunol. 2009 Apr;21(2):215-23. doi: 10.1016/j.coi.2009.02.009. Epub 2009 Mar 25.
3
Viral Engineering of Chimeric Antigen Receptor Expression on Murine and Human T Lymphocytes.
Methods Mol Biol. 2016;1458:137-57. doi: 10.1007/978-1-4939-3801-8_11.
4
Chimeric Antigen Receptor T Cells: Extending Translation from Liquid to Solid Tumors.
Hum Gene Ther. 2018 Oct;29(10):1083-1097. doi: 10.1089/hum.2017.251. Epub 2018 Aug 29.
5
Chimeric antigen receptors for T cell immunotherapy: current understanding and future directions.
J Gene Med. 2012 Jun;14(6):405-15. doi: 10.1002/jgm.2604.
6
Prospects for chimeric antigen receptor-modified T cell therapy for solid tumors.
Mol Cancer. 2018 Jan 12;17(1):7. doi: 10.1186/s12943-018-0759-3.
7
Engineering CAR-T Cells for Next-Generation Cancer Therapy.
Cancer Cell. 2020 Oct 12;38(4):473-488. doi: 10.1016/j.ccell.2020.07.005. Epub 2020 Jul 30.
8
Perspectives on Chimeric Antigen Receptor T-Cell Immunotherapy for Solid Tumors.
Front Immunol. 2018 May 22;9:1104. doi: 10.3389/fimmu.2018.01104. eCollection 2018.
9
CARs: Synthetic Immunoreceptors for Cancer Therapy and Beyond.
Trends Mol Med. 2017 May;23(5):430-450. doi: 10.1016/j.molmed.2017.03.002. Epub 2017 Apr 13.
10
Paving New Roads for CARs.
Trends Cancer. 2019 Oct;5(10):583-592. doi: 10.1016/j.trecan.2019.09.005. Epub 2019 Oct 19.
引用本文的文献
1
Targets for CAR Therapy in Multiple Myeloma.
Int J Mol Sci. 2025 Jun 24;26(13):6051. doi: 10.3390/ijms26136051.
2
Role of the tumor microenvironment in cancer therapy: unveiling new targets to overcome drug resistance.
Med Oncol. 2025 May 7;42(6):202. doi: 10.1007/s12032-025-02754-w.
3
Chimeric Antigen Receptor-T Cells in Colorectal Cancer: Pioneering New Avenues in Solid Tumor Immunotherapy.
J Clin Oncol. 2025 Mar 10;43(8):994-1005. doi: 10.1200/JCO-24-02081. Epub 2025 Jan 13.
4
Armoring chimeric antigen receptor (CAR) T cells as micropharmacies for cancer therapy.
Immunooncol Technol. 2024 Sep 25;24:100739. doi: 10.1016/j.iotech.2024.100739. eCollection 2024 Dec.
本文引用的文献
1
Expressing IL-15/IL-18 and CXCR2 improve infiltration and survival of EGFRvIII-targeting CAR-T cells in breast cancer.
Biochem Pharmacol. 2023 Jun;212:115536. doi: 10.1016/j.bcp.2023.115536. Epub 2023 Apr 5.
2
Metabolic reprogramming via an engineered PGC-1α improves human chimeric antigen receptor T-cell therapy against solid tumors.
J Immunother Cancer. 2023 Mar;11(3). doi: 10.1136/jitc-2022-006522.
3
Selective homing of CAR-CIK cells to the bone marrow niche enhances control of the acute myeloid leukemia burden.
Blood. 2023 May 25;141(21):2587-2598. doi: 10.1182/blood.2022018330.
4
Potentiating antibody-dependent killing of cancers with CAR T cells secreting CD47-SIRPα checkpoint blocker.
Blood. 2023 Apr 20;141(16):2003-2015. doi: 10.1182/blood.2022016101.
5
Next generations of CAR-T cells - new therapeutic opportunities in hematology?
Front Immunol. 2022 Oct 28;13:1034707. doi: 10.3389/fimmu.2022.1034707. eCollection 2022.
6
Migratory Engineering of T Cells for Cancer Therapy.
Vaccines (Basel). 2022 Oct 31;10(11):1845. doi: 10.3390/vaccines10111845.
7
CAR-T Cell Therapy in Hematological Malignancies: Current Opportunities and Challenges.
Front Immunol. 2022 Jun 10;13:927153. doi: 10.3389/fimmu.2022.927153. eCollection 2022.
8
CXCR4 and anti-BCMA CAR co-modified natural killer cells suppress multiple myeloma progression in a xenograft mouse model.
Cancer Gene Ther. 2022 May;29(5):475-483. doi: 10.1038/s41417-021-00365-x. Epub 2021 Sep 1.
9
Human Hyaluronidase PH20 Potentiates the Antitumor Activities of Mesothelin-Specific CAR-T Cells Against Gastric Cancer.
Front Immunol. 2021 Jul 13;12:660488. doi: 10.3389/fimmu.2021.660488. eCollection 2021.
10
Rapamycin Pretreatment Rescues the Bone Marrow AML Cell Elimination Capacity of CAR-T Cells.
Clin Cancer Res. 2021 Nov 1;27(21):6026-6038. doi: 10.1158/1078-0432.CCR-21-0452. Epub 2021 Jul 7.
Zotero 插件